Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    INFLAMMATORY BOWEL DISEASE 19
Show Display Options
Rank Status Study
1 Completed Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.
Condition: Crohn Disease
Interventions: Drug: ABBV-066;   Drug: Placebo

Study has passed its completion date and status has not been verified in more than two years.